Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis

American Heart Journal

Volumn 141, Issue 6, 2001, Pages 899-907

  Packer, Milton ^a   Antonopoulos, George V ^b   Berlin, Jesse A ^c   Chittams, Jesse ^c   Konstam, Marvin A ^b   Udelson, James E ^b  

^a College of Physicians and Surgeons ^*  (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; METOPROLOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035370722     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2001.115584     Document Type: Article

References (57)

1. Packer M, Bristow MR, Cohn JN, et al. Effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996;334:1349-55.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study-II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. Domanski MJ, BEST Investigators. Beta-blocker Evaluation of Survival Trial (BEST). J Am Coll Cardiol 2000;35:202-3A.
5. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1-6.
6. Willette RN, Aiyar N, Vue TL, et al. In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats. J Pharmacol Exp Ther 1999;389:48-53.
7. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39-52.
8. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
9. Flesch M, Ettelbrueck S, Rosenkranz S, et al. Differential effects of carvedilol and metoprolol on β-adrenergic signalling in cardiac myocytes. Circulation 1999;100(1 Suppl):I202.
10. Dandona P, Karne R, Ghanim H, et al. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000;101:122-4.
11. Ohlstein EH, Arleth AJ, Storer B, et al. Carvedilol inhibits endothelin-1 biosynthesis in cultured human coronary artery endothelial cells. J Mol Cell Cardiol 1998;30:167-73.
12. 1-selective and nonselective β-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996;94:353-8.
13. 2-Adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. Circulation 2000;101:71-7.
14. Grupp IL, Lorenz JN, Walsh RA, et al. Overexpression of alpha 1β-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy. Am J Physiol 1998;275:H1338-50.
15. Meredith IT, Broughton A, Jennings GL, et al. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618-24.
16. B receptor antagonist. Circulation 1996;93:2068-79.
17. Qin F, Shite J, Liand C-S. Reduction of oxidative stress by Trolox and superoxide dismutase abolishes norepinephrine-induced myocyte apoptosis and β-adrenergic receptor down-regulation in ferrets [abstract]. J Am Coll Cardiol 2000;35:168-9A.
18. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995;25:1154-61.
19. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-20.
20. Follman D, Elliott P, Suh I, et al. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992;45:769-73.
21. Bristow M, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
22. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate-to-severe heart failure. Circulation 1996;94:2793-9.
23. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
24. Cohn JN, Fowler MB, Bristow MB, et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-9.
25. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45.
26. Berkey CS, Hoaglin DC, Mosteller GA. A random-effects regression model for meta-analysis. Stat Med 1995;14:395-411.
27. Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-51.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
29. Egger M, Davey Smoth G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
30. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997;50:683-91.
31. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-41.
32. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 1994;89:1632-42.
33. Metra M, Nardi M, Giubbini R, et al. Effects of short- and long-term carvedilol administration on rest and hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
34. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
35. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
36. Australia-New Zealand Heart Failure Research Collaborative Group. Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-80.
37. Guazzi M, Agostoni P, Matturri M, et al. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999;138:460-7.
38. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
39. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-6.
40. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994;23:943-50.
41. Goldstein S, Kennedy HL, Hall C, et al. Metoprolol CR/XL in patients with heart failure: a pilot study examining the tolerability, safety, and effect on left ventricular ejection fraction. Am Heart J 1999;138:1158-65.
42. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The Randomized Evaluation of Strategies for Left Ventricular Pilot Study. Circulation 2000;101:378-84.
43. Sanderson JE, Chan SK, Yu CM, et al. Beta blockers in heart failure: a comparison of a vasodilating beta blocker with metoprolol. Heart 1998;79:86-92.
44. DiLenarda A, Sabbadini G, Salvatore L, et al. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926-34.
45. Metra M, Modena M, Giubbini R, et al. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation (in press).
46. Kukin ML, Kalman J, Charney RH, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
47. Sanderson JE, Chan SKW, Yip G, et al. Beta-blockade in heart failure. A comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999;34:1522-8.
48. Sandberg A, Blomqvist I, Jonsson DE, et al. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: a comparison with conventional tablets. Eur J Clin Pharmacol 1988;33(Suppl):S9-14.
49. Luecker P, Moore G, Wieselgren I, et al. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses. J Clin Pharmacol 1990;30:S17-27.
50. Bristow MR, Anderson FL, Port JD, et al. Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-39.
51. Bohm M, Gierschik P, Jakobs KH, et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-65.
52. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1998;259:539-44.
53. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
54. Cintron G, Johnson G, Francis G, et al. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure: the V-HeFT VA Cooperative Studies Group. Circulation 1993;87(6 Suppl):17-23.
55. Antonopoulos GV, Lao J, Konstam MA, et al. Are drug-induced changes in left ventricular ejection fraction or volumes adequate surrogates for long-term natural history outcomes in heart failure [abstract]? Circulation 1999;100(1 Suppl):I296.
56. Francis GS, Cohn JN. Heart failure: mechanisms of cardiac and vascular dysfunction and the rationale for pharmacologic intervention. FASEB J 1990;4:3068-75.
57. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;335:1107-14.